Key Market Indicator:
F&G: 40
25.233,35 NASDAQ · 48.573,00 DOW · 6.841,40 S&P · 4.299,43 Gold · 61,01 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
FR0010259150
Filter zurücksetzen
© Globe Newswire
19.03.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Article
News Preview
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
Article
News Preview
PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025.  She will serve on Ipsen’s Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this new...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
21.02.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen S.A. publishes its 2024 consolidated financial statements
Article
News Preview
Ipsen S.A. - 2024 Consolidated Financial Statements...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
13.02.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
Article
News Preview
PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - Half year statement - 2024 12 31
Article
News Preview
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Article
News Preview
PARIS, FRANCE; 03 December 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated Invariant T cells (MAIT cells) and targets the GPC3 tumor antigen, t...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Article
News Preview
PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial I...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Article
News Preview
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for the Study of Liver Disease (AASLD) congress. The late-breaking presentations (Abstra...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
07.11.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
Article
News Preview
PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen receives its second Shingo Prize for operational excellence
Article
News Preview
PARIS, FRANCE, 14 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has received the Shingo Prize for operational excellence. This is Ipsen’s second Shingo Prize, with its site in Signes, France, receiving the first award in 2020....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Article
News Preview
                                                                ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Article
News Preview
PARIS, FRANCE, 15 September 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today detailed final overall survival (OS) data from the Phase III CONTACT-02 trial investigating the combination of Cabometyx® (cabozantinib) and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC). The trial investigated the combination regimen vers...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Article
News Preview
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Article
News Preview
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
Article
News Preview
PARIS, FRANCE, 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
Article
News Preview
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
Article
News Preview
Aggregated presentation by day and by market  ...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
Article
News Preview
PARIS, FRANCE, 11 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role i...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Half-year statement of IPSEN liquidity agreement - 2024 06 30
Article
News Preview
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
Article
News Preview
PARIS, FRANCE, 2 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® (cabozantinib) in advanced pancreatic neuroendocrine tumors (pNETs) and advanced extra-pancreatic neuroendocrine tumors (epNETs). The agreement is based...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
Article
News Preview
Aggregated presentation by day and by market...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Article
News Preview
                                                                        ...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
Article
News Preview
PARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics Inc, a clinical-stage biotech company, announced today the expansion of their ongoing oncology research partnership, to include TriSTAR, Marengo’s next-generation, precision T cell engager (TCE) technology. Traditional TCEs targeting ‘c...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    
Article
News Preview
PARIS, FRANCE, DD June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced new late-breaking data at the European Association for the Study of the Liver (EASL) Congress demonstrating the enduring efficacy of elafibranor in managing disease progression after 78 weeks of treatment. In the variable double-blind period of the ELATIVE® Phase III tri...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
Article
News Preview
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen announces the launch of an employee shareholding plan
Article
News Preview
Ipsen announces the launch of an employee shareholding plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Annual General Meeting of Ipsen S.A. held on 28 May 2024
Article
News Preview
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors, and in the presence of the members of the Board of Directors and...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
Article
News Preview
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, the Delegated Regulation No 2016/1052 of 8 March 2016, and the General Regulation of the French Autorité des Marchés Fin...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2024
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Article
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 14.12.2025, Calendar Week 50, 348th day of the year, 17 days remaining until EoY.